Baxter International

Profile narrative

Baxter International is a global healthcare company that develops, manufactures, and markets a broad portfolio of medical products and services. Its core offerings include renal care solutions such as dialysis machines and peritoneal dialysis supplies, intravenous (IV) therapies, medication delivery systems, and nutrition products. The company also provides pharmaceutical products, biosimilars, and advanced therapy platforms for conditions like hemophilia and immune disorders. Baxter serves hospitals, clinics, home care providers, and patients across acute and chronic care settings worldwide. The company continues to invest in research and development to advance next‑generation therapies and improve existing product lines.

Headquartered in Deerfield, Illinois, United States, Baxter operates in more than 100 countries and maintains manufacturing, research, and distribution facilities across North America, Europe, Asia, and Latin America. As a publicly traded corporation listed on the New York Stock Exchange under the ticker BAX, it reports annual revenues in the billions of dollars and employs a workforce that spans tens of thousands of employees. Its global footprint enables the company to address diverse healthcare needs in both developed and emerging markets. The company’s supply chain is designed to ensure reliable delivery of critical medical products to healthcare facilities worldwide.

Baxter is distinguished by its longstanding specialization in renal care, having pioneered dialysis technologies that support millions of patients with kidney failure. The company also holds a significant position in the IV therapy market, offering smart infusion pumps, safety‑engineered catheters, and compounding solutions designed to reduce medication errors. In addition, Baxter invests heavily in biologics and biosimilars, aiming to expand access to high‑cost therapies while maintaining stringent regulatory compliance with agencies such as the U.S. Food and Drug Administration and the European Medicines Agency.

Structurally, Baxter International remains an independent, publicly traded entity with no parent company; it oversees a network of wholly owned subsidiaries that manage regional operations, product lines, and specialized business units. Governance is conducted through a board of directors and executive leadership team responsible for strategic direction, operational oversight, and accountability to shareholders. The company’s organizational structure supports its focus on innovation, operational efficiency, and sustained growth in the global healthcare sector.

Incidents

1 incident linked to this organisation.